Pharma Focus America

Spine BioPharma, Inc. and Ensol BioSciences, Inc. have reached an agreement to broaden the applications of SB-01 For Injection

Thursday, July 11, 2024

Spine BioPharma, Inc., a company focused on developing non-opioid, non-surgical therapies for pain-related disabilities, has announced a significant agreement with Ensol BioSciences, Inc., a Korean company. Valued at $155 million, this agreement grants Spine BioPharma exclusive rights to expand the therapeutic applications of its candidate drug, SB-01 For Injection.

Initially licensed by Yuhan Corporation from Ensol BioSciences in 2018 and subsequently acquired globally (excluding Korea) by Spine BioPharma, SB-01 For Injection is currently undergoing Phase 3 trials for moderate-to-severe degenerative disc disease (DDD). The completion of enrollment in the 400-patient MODEL Study is expected by September 2024 ( NCT05516992).

Spine BioPharma, expressed optimism about the agreement, highlighting its potential to broaden SB-01's therapeutic scope beyond spine-related diseases to include osteoarthritis, fibrotic diseases, and oncological indications. SB-01 modulates TGF-Beta, a cytokine involved in various disease mechanisms, without eliminating it, potentially addressing diverse medical needs.

This strategic partnership underscores Spine BioPharma's commitment to addressing unmet needs among patients suffering from pain-related disabilities and beyond, positioning SB-01 as a promising candidate across multiple therapeutic areas.



Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024